DNMT3A and prostate carcinoma: A case study documented the detection of high-risk CH variants DNMT3A exon 23 p.R882H and isocitrate dehydrogenase 2 (IDH2) exon 4 p.R140Q at a low VAF in a patient with prostate cancer who developed acute myeloid leukemia a year later, driven by the same mutations [98].